EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts

Daniela Zanetti, Laurel Stell, Stefan Gustafsson, Fahim Abbasi, Philip S Tsao, Joshua W Knowles, RISC Investigators, Björn Zethelius, Johan Ärnlöv, Beverley Balkau, Mark Walker, Laura C Lazzeroni and 3 more

Diabetologia · 2023-09 · 66 (9) · 1643-1654

DOI: 10.1007/s00125-023-05946-z ↗

At a glance

Journal article in Diabetologia, published online on 2023-06-17. Written by Daniela Zanetti and 14 co-authors. Institution: Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. Major MEDLINE topics: Insulin Resistance, Cardiovascular Diseases. Cited 17 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, NIH HHS, Foundation for the National Institutes of Health.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aims/hypothesis The euglycaemic–hyperinsulinaemic clamp (EIC) is the reference standard for the measurement of whole-body insulin sensitivity but is laborious and expensive to perform. We aimed to assess the incremental value of high-throughput plasma proteomic profiling in developing signatures correlating with the M value derived from the EIC.

Methods

We measured 828 proteins in the fasting plasma of 966 participants from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study and 745 participants from the Uppsala Longitudinal Study of Adult Men (ULSAM) using a high-throughput proximity extension assay. We used the least absolute shrinkage and selection operator (LASSO) approach using clinical variables and protein measures as features. Models were tested within and across cohorts. Our primary model performance metric was the proportion of the M value variance explained ( R 2 ).

Results

A standard LASSO model incorporating 53 proteins in addition to routinely available clinical variables increased the M value R 2 from 0.237 (95% CI 0.178, 0.303) to 0.456 (0.372, 0.536) in RISC. A similar pattern was observed in ULSAM, in which the M value R 2 increased from 0.443 (0.360, 0.530) to 0.632 (0.569, 0.698) with the addition of 61 proteins. Models trained in one cohort and tested in the other also demonstrated significant improvements in R 2 despite differences in baseline cohort characteristics and clamp methodology (RISC to ULSAM: 0.491 [0.433, 0.539] for 51 proteins; ULSAM to RISC: 0.369 [0.331, 0.416] for 67 proteins). A randomised LASSO and stability selection algorithm selected only two proteins per cohort (three unique proteins), which improved R 2 but to a lesser degree than in standard LASSO models: 0.352 (0.266, 0.439) in RISC and 0.495 (0.404, 0.585) in ULSAM. Reductions in improvements of R 2 with randomised LASSO and stability selection were less marked in cross-cohort analyses (RISC to ULSAM R 2 0.444 [0.391, 0.497]; ULSAM to RISC R 2 0.348 [0.300, 0.396]). Models of proteins alone were as effective as models that included both clinical variables and proteins using either standard or randomised LASSO. The single most consistently selected protein across all analyses and models was IGF-binding protein 2. Conclusions/interpretation A plasma proteomic signature identified using a standard LASSO approach improves the cross-sectional estimation of the M value over routine clinical variables. However, a small subset of these proteins identified using a stability selection algorithm affords much of this improvement, especially when considering cross-cohort analyses. Our approach provides opportunities to improve the identification of insulin-resistant individuals at risk of insulin resistance-related adverse health consequences. Graphical Abstract

Subjects

MeSH terms (MEDLINE)

Insulin ResistanceCardiovascular DiseasesMaleAdultHumansLongitudinal StudiesProteomicsCross-Sectional StudiesInsulin

Author keywords

Euglycaemic–hyperinsulinaemic clampInsulin resistanceInsulin sensitivityLASSOPlasma proteomicsPopulation studyStability selection

Substances

Insulin

Authors and institutions

  • Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.

Funding

  • NIDDK NIH HHS
  • NIH HHS
  • Foundation for the National Institutes of Health

Cite

APA

Zanetti, D., Stell, L., Gustafsson, S., Abbasi, F., Tsao, P. S., Knowles, J. W., RISC Investigators, Zethelius, B., Ärnlöv, J., Balkau, B., Walker, M., Lazzeroni, L. C., Lind, L., Petrie, J. R., & Assimes, T. L. (2023). Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts. Diabetologia, 66(9), 1643-1654. https://doi.org/10.1007/s00125-023-05946-z

Vancouver

Zanetti D, Stell L, Gustafsson S, Abbasi F, Tsao PS, Knowles JW, et al. Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts. Diabetologia. 2023;66(9):1643-1654. doi:10.1007/s00125-023-05946-z

BibTeX
@article{Zanetti2023,
  author = {Zanetti, Daniela and Stell, Laurel and Gustafsson, Stefan and Abbasi, Fahim and Tsao, Philip S and Knowles, Joshua W and RISC Investigators, RISC Investigators and Zethelius, Björn and Ärnlöv, Johan and Balkau, Beverley and Walker, Mark and Lazzeroni, Laura C and Lind, Lars and Petrie, John R and Assimes, Themistocles L},
  title = {Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts},
  journal = {Diabetologia},
  year = {2023},
  volume = {66},
  number = {9},
  pages = {1643--1654},
  doi = {10.1007/s00125-023-05946-z}
}
Start for free →